

Dairy product consumption and its association with metabolic disturbance in a prospective study of urban adults

May A. Beydoun^{1*}, Marie T. Fanelli-Kuczmariski², Hind A. Beydoun³, Greg A. Dore¹, Jose A. Canas⁴, Michele K. Evans^{1†} and Alan B. Zonderman^{1†}

¹Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institute on Aging, National Institutes of Health, Intramural Research Program, Baltimore, MD 21224, USA

²Department of Behavioral Health and Nutrition, University of Delaware, Newark, DE 19716, USA

³Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA

⁴Nemours Children's Clinic, Jacksonville, FL 32207, USA

(Submitted 21 September 2017 – Final revision received 14 December 2017 – Accepted 2 January 2018)

Abstract

The role of dairy foods and related nutrients in cardiometabolic health aetiology is poorly understood. We investigated longitudinal associations between the metabolic syndrome (MetS) and its components with key dairy product exposures. We used prospective data from a bi-racial cohort of urban adults (30–64 years at baseline (*n* 1371)), the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS), in Baltimore City, MD (2004–2013). The average of two 24-h dietary recalls measured 4–10 d apart was computed at baseline (V1) and follow-up (V2) waves. Annual rates of change (Δ) in dairy foods and key nutrients were estimated. Incident obesity, central obesity and the MetS were determined. Among key findings, in the overall urban adult population, both cheese and yogurt (V1 and Δ) were associated with an increased risk of central obesity (hazard ratio (HR) 1.13; 95% CI 1.05, 1.23 per oz equivalent of cheese (V1); HR 1.21; 95% CI 1.01, 1.44 per fl oz equivalent of yogurt (V1)). Baseline fluid milk intake (V1 in cup equivalents) was inversely related to the MetS (HR 0.86; 95% CI 0.78, 0.94), specifically to dyslipidaemia–TAG (HR 0.89; 95% CI 0.81, 0.99), although it was directly associated with dyslipidaemia–HDL-cholesterol (HR 1.10; 95% CI 1.01, 1.21). Furthermore, Δ Ca and Δ P were inversely related to dyslipidaemia–HDL and MetS incidence, respectively, whereas Δ dairy product fat was positively associated with incident TAG–dyslipidaemia and HDL-cholesterol–dyslipidaemia and the MetS. A few of those associations were sex and race specific. In sum, various dairy product exposures had differential associations with metabolic disturbances. Future intervention studies should uncover how changes in dairy product components over time may affect metabolic disorders.

Key words: Dairy product consumption: Calcium: Obesity: Metabolic syndrome: Urban adults

The metabolic syndrome (MetS) is a clustering of cardiometabolic risk factors, namely central obesity, hyperglycaemia, hypertension and dyslipidaemia (hypertriglycerolaemia and reduced HDL-cholesterol)⁽¹⁾. By increasing CVD and type 2 diabetes risk by 1.7- and 5-fold^(2,3), respectively, the MetS is a threat to public health, with rising all-cause mortality rates, disability and health-care costs^(4–12). Dairy product consumption's effect on the MetS remains controversial⁽¹³⁾. Among dairy product constituents, SFA shows deleterious effect on weight and CVD^(14–18), whereas Ca and Mg may carry beneficial effects^(13,19–27). Notably, dietary Ca, a key weight regulator, affects adipocyte intracellular Ca concentration, thus decreasing fatty acid synthesis, while up-regulating lipolysis and reducing net TAG stores^(24,28).

Most guidelines recommend 2–3 dairy product servings/d, a goal unreachable by many US adults⁽²³⁾. Optimal dairy product

intake may prevent adverse health outcomes and related risk factors, including obesity, central obesity and the MetS⁽²³⁾. Recent observational and experimental studies suggest that dairy product and Ca consumption may reduce obesity risk^(29,30), excess central⁽³¹⁾ fat distribution, type 2 diabetes^(32,33), hypertension⁽³⁴⁾ and the MetS^(31,34–68), whereas mixed or negative findings were reported by others^(69–83).

To our knowledge, our study is the first to assess, in an urban population, the association between consumption of dairy foods and related nutrients and obesity, central obesity and the MetS, with repeated measures on dietary and metabolic parameters. We further examined socio-demographic correlates of dairy foods, dairy-related nutrient intakes and metabolic disturbances (MetD). Finally, we tested sex- and race-specific associations between dairy product intake and MetD.

Abbreviations: HANDLS, Healthy Aging In Neighborhoods of Diversity across the Life Span; MetD, metabolic disturbances; MetS, metabolic syndrome; WC, waist circumference.

* **Corresponding author:** M. A. Beydoun, fax +1 410 558 8236, email baydounm@mail.nih.gov

† Co-senior authors.

Methods

Database

Initiated in 2004, the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study is a prospective, population-based, longitudinal study. The sample is a fixed cohort of participants based on household screenings from an area probability sample of thirteen neighbourhoods (areas of contiguous census tracts) in Baltimore City, MD. Neighbourhoods were selected to yield sufficient numbers of participants to fill a four-way design of race, sex, age and socio-economic status assessed by 125% of the Federal poverty level. Recruitment and sampling contractors produced household listings to identify residential dwellings in each neighbourhood. The contractors performed doorstep interviews, identified eligible persons in each household, selected one of two eligible persons per household and invited the eligible candidates to participate in HANDLS. Participants had to be aged 30–64 years, to self-identify as White or African-American, have the ability to give informed consent, perform at least five study measures and present valid picture identification. Individuals were excluded from the study if they were pregnant, within 6 months of active cancer treatment, or multiethnic individuals who did not identify strongly with either the Black or White race⁽⁸⁴⁾. The present study uses baseline visit 1 (V1: 2004–2009) and the first follow-up visit 2 (V2: 2009–2013). All participants

provided written informed consent, after accessing a protocol booklet in layman’s terms and a video detailing all procedures and future re-contacts. HANDLS study was ethically approved by the National Institute on Environmental Health Sciences, National Institutes of Health Institutional Review Board.

Study participants

Of the original HANDLS sample (*n* 3720), 24-h dietary recall data were collected for each of the two visits (i.e. V1 and V2) for 1513 participants (sample 2, Fig. 1). Among those, data were complete on metabolic outcomes at each of the two visits as outlined in Fig. 1 (samples 3a–3h). The final analytic samples consisted of individuals with complete data on dietary intakes and metabolic outcomes at both visits (sample 5h, Fig. 1: *n* 1371), and MetD-free participants for each of the metabolic outcomes (samples 6a, 6b (*n* 588–859) and 7a–7d (*n* 915–1171), Fig. 1). Mean follow-up time with their standard errors was estimated at 4.62 (SE 0.95) years (range: 0.42–8.20).

Dietary assessment

At each visit, the average nutrient and food group intakes from two 24-h dietary recalls were estimated. Each 24-h dietary recall was obtained using the US Department of Agriculture (USDA)




Fig. 1. Participant flow chart. HANDLS, Healthy Aging in Neighborhoods of Diversity across the Life Span; AA, African-Americans; SRH, self-rated health; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; MetD, metabolic disturbances; MetS, metabolic syndrome.

Automated Multiple Pass Method, a computerised structured interview⁽⁸⁵⁾ utilising measurement aids (e.g. cups, spoons, ruler, illustrated Food Model Booklet). At first visit, both recalls were administered in-person by trained interviewers, 4–10 d apart, whereas at follow-up (visit 2) the second recall was administered using telephone interviews. Using Survey Net, trained nutrition professionals matched foods consumed with eight-digit codes from the Food and Nutrient Database for Dietary Studies version 3.0⁽⁸⁶⁾, and MyPyramid equivalents database was used to create food groups (MPED 2: http://www.ars.usda.gov/SP2UserFiles/Place/80400530/pdf/mped/mped2_doc.pdf).

Dietary exposures

Dietary exposures of interest included the following: (1) dairy foods, namely, total dairy product intake (servings/d), total fluid milk intake (servings/d), total cheese intake (servings/d) and total yogurt intake (servings/d) – one serving of dairy food is calculated in terms of cup equivalents, and thus for milk a serving is 1 cup, whereas for cheese it ranges between 1.5 oz for hard cheese to two cups for ricotta cheese, and for yogurt, on the other hand, a serving is 1 cup or 8 fl oz; and (2) dairy-related nutrients, namely Ca (mg/d), Mg (mg/d), P (mg/d) and dairy product fat % of total fat (myristic acid (14:0) × 100/total fat). Fluid milk was also categorised into whole *v.* reduced fat milk (g/d), whereas DRI of Ca and total dairy products consumption were estimated. Key exposures were measured as baseline (V1) values and annualised rates of change (i.e. Δ dairy products = (dairy product_{follow} – dairy product_{base})/(Age_{follow} – Age_{base})).

Anthropometric measures and metabolic outcome variables

BMI and waist circumference. BMI (weight/height² (kg/m²)) was calculated for each participant using measured weight and height. Waist circumference (WC (cm)) was measured using a tape measure starting from the hip bone and wrapping around the waist at the level of the navel.

Systolic and diastolic blood pressure. Systolic and diastolic blood pressure levels (SBP and DBP) were measured by averaging right and left sitting non-invasive assessments using brachial artery auscultation with an aneroid manometer, a stethoscope and an inflatable cuff.

Other metabolic risk factors. After an overnight fast (8–12 h), blood was drawn and collected from an antecubital vein. Total cholesterol, HDL-cholesterol, TAG and fasting glucose were assessed using a spectrophotometer (AU5400 High-Volume Chemistry Immuno Analyzer; Olympus Global).

Classification of key health outcomes

Obesity was defined as BMI ≥ 30 kg/m², and central obesity as WC ≥ 102 cm or 40 inches (men), ≥ 88 cm or 35 inches (women)⁽⁸⁷⁾.

Participants were classified as MetS-positive if they screened positive on at least three of five conditions⁽¹⁾ – (1) central

obesity (see above); (2) dyslipidaemia: TAG ≥ 1.695 mmol/l (150 mg/dl); (3) dyslipidaemia: HDL-cholesterol < 40 mg/dl (male), < 50 mg/dl (female); (4) blood pressure $\geq 130/85$ mmHg; and (5) fasting plasma glucose ≥ 6.1 mmol/l (110 mg/dl)⁽⁸⁸⁾. Similarly, continuous annual rates of change (Δ) in metabolic outcomes were considered, namely number of MetD, BMI, WC, SBP, DBP, TAG, HDL-cholesterol and glucose. Binary incident outcomes were obesity, central obesity, the MetS and other MetD (i.e. hypertension, dyslipidaemia–TAG, dyslipidaemia–HDL and hyperglycaemia).

Covariates

Covariates included in our analyses were baseline age, sex, race, poverty status, education, self-rated health, smoking and drug use among fixed or baseline covariates. Annual rates of change (Δ) in covariates were considered, except when baseline dairy product exposures were examined. Those were total energy intake (kJ/d (kcal/d)), caffeine intake (mg/d) and MyPyramid equivalents of total fruit, dark green and orange vegetables, whole and non-whole grains, legumes, nuts/seeds, soya, total meat/poultry/fish, eggs, discretionary solid fat and oils (g), added sugars (teaspoons) and alcoholic beverages (servings).

Statistical analyses

Using Stata release 14.0⁽⁸⁹⁾, we first described the sex and race differences in dairy product consumption and metabolic outcomes, comparing means using independent samples *t*-tests, and testing associations with χ^2 tests. Second, Cox proportional hazards (PH) regression models were fit to test independent associations of socio-demographic factors with dairy product consumption and incident metabolic outcomes.

Importantly, two sets of models included as exposures dairy foods (model 1) and dairy-related nutrients (model 2), respectively. Cox PH models tested associations of baseline dairy products (V1) and Δ dairy product exposures with incident binary metabolic outcomes. To account for potential selection bias in our multivariate models due to the non-random selection of participants with complete data from the target study population, a two-stage Heckman selection process was used⁽⁹⁰⁾. A probit model was constructed to obtain an inverse mills ratio at the first stage (derived from the predicted probability of being selected, conditional on the covariates in the probit model, mainly baseline age, sex, race, poverty status and education), as was done in earlier studies^(91–93). This inverse mills ratio was then entered as a covariate in the main models to adjust for sample selectivity. Type I error was set at 0.05.

Results

Baseline study characteristics

Key study characteristics and socio-demographic correlates of dairy product consumption and metabolic outcomes are presented in Table 1. Our final sample of 1371 urban adults had a mean age of 48.4 with an SE of 0.24, with 40.6% being men and 48.5% being African-American. Only 36.6% had > High school educational attainment and the proportion above poverty was

Table 1. Sex and racial differences in intakes of dairy foods and related nutrients, obesity and metabolic outcomes: Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) 2004–2009 and 2009–2013 (Percentages; mean values with their standard errors)

	All (n 1371)		Men (n 557)		Women (n 814)		Whites (n 568)		African-Americans (n 803)	
	Mean	SE	Mean	SE	Mean	SE	Mean	SE	Mean	SE
Socio-demographic and health characteristics, V1										
Age (years)	48.4	0.24	48.6	0.4	48.2	0.3	48.9	0.4	48.0	0.3
Men (%)	40.6		–		–		39.8		41.2	
African-American (%)	58.6		59.4		58.0		–		–	
Above poverty (%)	60.1		63.9		57.5*		70.1		53.1*	
Education (%)										
< High school	6.8		8.4		5.6		9.5		4.9*	
High school	56.6		55.8		57.0		50.0		61.3	
> High school	36.6		35.7		37.1		40.5		33.9	
Self-rated health (%)										
Poor/fair	22.8		23.2		22.6		24.1		21.9*	
Good	41.2		39.5		42.4		37.2		44.0	
Very good/excellent	36.0		37.3		35.1		38.7		34.1	
Current smoker, yes (%)	40.5		43.8		38.2		36.7		43.2*	
Current smoker, missing (%)	8.1		8.1		8.1		8.4		7.9	
Current illicit drug user, yes (%)	15.6		20.5		12.3*		11.4		18.6*	
Current illicit drug user, missing (%)	8.1		8.1		8.1		8.4		7.9	
Dairy products and related nutrients, V1										
Fluid milk (g)										
All milk (g)	64.3	2.9	66.1	4.4	63.0	3.9	93.2	5.5	43.8*	3.0
Whole milk (g)	32.4	2.2	34.0	3.3	31.4	2.9	41.5	4.1	25.9*	2.3
Low-fat/fat-free milk (g)	31.8	2.2	32.1	3.2	31.6	3.0	51.7	4.4	17.9*	2.0
All dairy products (servings)	1.02	0.03	1.15	0.04	0.93*	0.03	1.33	0.05	0.80*	0.03
All dairy products, ≥3 servings/d (%)	4.96		6.64		3.81*		8.98		2.12*	
Fluid milk (servings)	0.51	0.02	0.56	0.03	0.47*	0.02	0.67	0.03	0.39*	0.02
Yogurt (servings)	0.027	0.003	0.022	0.005	0.030	0.005	0.042	0.006	0.016*	0.003
Cheese (servings)	0.48	0.02	0.56	0.03	0.42*	0.02	0.61	0.03	0.39*	0.02
Ca (mg/d)	725.6	11.7	821.9	20.2	659.7*	13.6	829.1	20	652.4*	14
Ca, > recommended mg/d (%)	18.3		26.8		12.5*		26.2		12.7*	
Mg (mg/d)	241.1	3.3	271.8	5.7	220.4*	3.8	266.5	5.6	223.5*	3.9
P (mg/d)	1141	15	1343	27	1004*	16	1231	25	1079*	19
Dairy product fatty acids (g/100 g fat)	2.44	0.04	2.34	0.05	2.51*	0.05	2.89	0.06	2.12*	0.04
Dairy products and related nutrients, Δ										
Fluid milk										
All milk (g)	+2.69	0.87	+2.45	1.26	+2.85	1.18	+4.27	1.67	+1.57	0.89
Whole milk (g)	+0.73	0.67	+0.91	1.03	+0.60	0.88	+1.80	1.28	–0.03	0.70
Low-fat/fat-free milk (g)	+1.96	0.65	+1.54	0.95	+2.25	0.89	+2.47	1.33	1.60	0.60
All dairy product (servings)	+0.05	0.01	+0.07	0.01	+0.04	0.01	+0.06	0.01	+0.05	0.01
Fluid milk (servings)	+0.02	0.01	+0.02	0.01	+0.02	0.01	+0.03	0.01	+0.02	0.01
Yogurt (servings)	+0.005	0.001	+0.004	0.002	+0.006	0.002	+0.008	0.003	+0.003	0.001
Cheese (servings)	+0.025	0.006	+0.034	0.010	+0.019	0.007	+0.022	0.012	+0.028	0.006
Ca (mg/d)	+34.6	3.6	+41.0	6.2	+30.3	4.3	+30.4	6.4	+37.7	4.1
Mg (mg/d)	+3.47	0.81	+3.62	1.44	+3.36	0.94	+1.92	1.43	+4.60	0.93
P (mg/d)	+25.7	4.0	+26.5	7.3	+25.2	4.5	+22.8	6.7	+27.8	4.8
Dairy products fatty acids (g/100 g fat)	+0.03	0.01	+0.03	0.02	+0.02	0.02	+0.04	0.02	+0.02	0.01
Other dietary factors, V1 and Δ										
Energy (kcal/d)†										
V1	2003	26	2382	46	1743*	26	2043	39	1974	34
Δ	+8.09	6.18	+3.59	11.54	+11.17	6.79	+0.19	10.48	+13.7	7.51
Total fruits (servings)										
V1	0.73	0.03	0.81	0.05	0.67	0.03	0.76	0.05	0.70	0.03
Δ	+0.026	0.008	+0.019	0.014	+0.030	0.009	+0.01	0.01	+0.03	0.01
Dark green vegetables (servings)										
V1	0.12	0.01	0.11	0.01	0.12	0.01	0.11	0.01	0.12	0.01
Δ	+0.009	0.002	+0.005	0.003	+0.012	0.003	+0.012	0.004	+0.007	0.003
Orange vegetables (servings)										
V1	0.068	0.004	0.066	0.006	0.069	0.006	0.087	0.007	0.054*	0.005
Δ	+0.042	0.002	+0.047	0.003	+0.039	0.003	+0.052	0.004	+0.036*	0.002
Whole grains (servings)										
V1	0.65	0.03	0.68	0.05	0.63	0.04	0.78	0.05	0.56*	0.03
Δ	+0.014	0.008	+0.015	0.014	+0.013	0.010	–0.006	0.014	+0.028*	0.009
Non-whole grains (servings)										
V1	5.30	0.09	6.39	0.16	4.55*	0.09	5.70	0.14	5.02*	0.11
Δ	–0.046	0.024	–0.087	0.042	–0.018	0.028	–0.089	0.040	–0.016	0.029

Table 1. *Continued*

	All (n 1371)		Men (n 557)		Women (n 814)		Whites (n 568)		African-Americans (n 803)	
	Mean	SE	Mean	SE	Mean	SE	Mean	SE	Mean	SE
Legumes (servings)										
V1	0.05	0.01	0.06	0.01	0.04	0.01	0.06	0.01	0.05	0.01
Δ	+0.032	0.004	+0.036	0.006	+0.028	0.005	+0.039	0.006	+0.026	0.005
Nuts/seeds (servings)										
V1	0.47	0.05	0.52	0.08	0.44	0.07	0.60	0.09	0.38*	0.07
Δ	+0.003	0.015	+0.019	0.023	-0.008	0.019	+0.007	0.026	+0.000	0.017
Soya (servings)										
V1	0.06	0.01	0.04	0.01	0.07	0.01	0.09	0.02	0.04*	0.01
Δ	-0.002	0.002	-0.001	0.001	-0.003	0.003	+0.007	0.026	+0.000	0.017
Meat, poultry, fish (servings)										
V1	5.49	0.11	6.82	0.21	4.59*	0.11	4.77	0.16	6.00*	0.15
Δ	-0.031	0.029	-0.063	0.054	-0.010	0.032	-0.056	0.045	-0.014	0.038
Eggs (servings)										
V1	0.58	0.02	0.74	0.04	0.47*	0.02	0.47	0.03	0.66*	0.03
Δ	+0.009	0.006	+0.006	0.011	+0.011	0.007	+0.016	0.011	+0.004	0.007
Discretionary fat (servings)										
V1	43.5	0.77	52.5	1.39	37.3*	0.82	45.2	1.3	42.3	1.0
Δ	-0.79	0.20	-1.04	0.38	-0.62	0.21	-1.16	0.36	-0.53	0.23
Discretionary oil (servings)										
V1	17.4	0.44	19.6	0.8	15.9*	0.5	17.6	0.6	17.3	0.6
Δ	+0.91	0.13	+1.15	0.23	+0.74	0.15	+1.01	0.21	+0.83	0.16
Added sugars (servings)										
V1	20.1	0.4	23.5	0.8	17.8*	0.5	20.0	0.7	20.2	0.5
Δ	+0.06	0.12	+0.02	0.20	+0.07	0.14	-0.10	0.21	+0.15	0.13
Alcoholic beverages (servings)										
V1	0.55	0.04	0.77	0.08	0.39*	0.04	0.54	0.07	0.55	0.06
Δ	-0.01	0.01	-0.01	0.02	-0.01	0.01	-0.00	0.02	-0.01	0.01
Caffeine (mg/d)										
V1	137.9	8.3	159.0	8.3	123.5*	5.5	227.5	9.3	74.6*	3.2
Δ	+0.60	1.01	-0.78	1.74	+1.55	1.22	-0.36	2.21	+1.28	0.73
Metabolic outcomes, V1, V2, Δ										
BMI (kg/m ²)										
V1	29.8	0.2	28.2	0.3	30.9*	0.3	29.8	0.3	29.9	0.3
V2	30.5	0.2	28.6	0.3	31.8*	0.3	30.4	0.3	30.5	0.3
Δ	+0.14	0.02	+0.09	0.03	+0.18*	0.03	+0.16	0.03	+0.13	0.03
Waist circumference (cm)										
V1	100.0	0.8	100.4	1.8	99.7	0.6	102.4	1.7	98.3*	0.6
V2	102.9	0.5	102.3	0.7	103.4	0.6	104.1	0.7	102.1*	0.6
Δ	+0.62	0.14	+0.41	0.34	+0.76	0.09	+0.40	0.34	+0.77	0.08
SBP (mmHg)										
V1	119.7	0.5	120.5	0.7	119.2	0.6	117.6	0.7	121.2*	0.6
V2	122.2	0.5	122.0	0.7	122.3	0.6	119.0	0.7	124.5*	0.6
Δ	+0.49	0.12	+0.27	0.17	+0.64	0.17	+0.23	0.21	+0.69	0.15
DBP (mmHg)										
V1	72.6	0.3	74.3	0.4	71.4*	0.4	71.8	0.4	73.1*	0.4
V2	70.8	0.3	72.3	0.4	69.7*	0.3	68.7	0.4	72.2*	0.4
Δ	-0.40	0.08	-0.44	0.12	-0.37	0.12	-0.73	0.15	-0.16*	0.10
HDL-cholesterol (mg/dl)†										
V1	53.1	0.5	48.8	0.7	56.0*	0.6	49.7	0.6	55.5*	0.6
V2	56.7	0.5	52.2	0.7	59.7*	0.6	52.7	0.7	59.5*	0.7
Δ	+0.79	0.08	+0.71	0.13	+0.85	0.10	+0.71	0.11	+0.85	0.11
TAG (mg/dl)†										
V1	124.0	2.6	138.0	5.1	114.4*	2.6	146.6	4.7	108.0*	2.8
V2	123.6	2.1	130.3	3.7	119.0*	2.4	143.5	4.0	109.4*	2.1
Δ	-0.06	0.49	-1.60	0.96	+1.00*	0.51	-0.66	0.95	+0.37	0.51
Fasting blood glucose (mg/dl)†										
V1	104.4	1.1	106.9	1.9	102.7	1.4	106.4	1.8	103.0	1.4
V2	104.5	1.1	108.5	2.0	101.7*	1.2	106.0	1.8	103.4	1.4
Δ	+0.06	0.24	+0.30	0.41	-0.10	0.29	+0.07	0.42	+0.06	0.27
Obesity (%; BMI ≥ 30 kg/m ²)										
V1		42.1		33.0		48.3*		41.7		42.3
V2		47.3		37.0		54.3*		47.5		47.1
Incident		14.0		11.6		16.1*		14.3		13.8
Central obesity (%)‡										
V1		59.8		40.9		72.7*		63.7		57.0*
V2		68.3		48.5		81.9*		71.5		66.0*
Incident		29.6		20.7		43.0*		30.5		29.1

Table 1. *Continued*

	All (n 1371)		Men (n 557)		Women (n 814)		Whites (n 568)		African-Americans (n 803)	
	Mean	SE	Mean	SE	Mean	SE	Mean	SE	Mean	SE
MetS (%)§										
V1			25.1		26.3		31.0		22.2*	
V2			22.3		28.3*		31.5		21.8*	
Incident			9.6		14.7*		14.5		11.4	
Number of metabolic disturbances§										
V1	1.66	0.03	1.49	0.06	1.78*	0.04	1.82	0.05	1.55*	0.04
V2	1.70	0.03	1.49	0.06	1.85*	0.04	1.81	0.06	1.62*	0.04
Δ	+0.006	0.007	-0.007	0.011	+0.014	0.009	-0.01	0.01	+0.01	0.01

V1, baseline visit 1; Δ, annual rate of change; V2, first follow-up visit 2; SBP, systolic blood pressure; DBP, diastolic blood pressure; MetS, metabolic syndrome.

* $P < 0.05$ for testing the null hypothesis that means or proportions are the same between groups.

† To convert kcal to kJ, multiply by 4.184. To convert HDL-cholesterol in mg/dl to mmol/l, multiply by 0.0259. To convert TAG in mg/dl to mmol/l, multiply by 0.0113. To convert glucose in mg/dl to mmol/l, multiply by 0.0555.

‡ Defined as waist circumference > 102 cm for men and > 88 cm for women.

§ Defined based on National Cholesterol Education Program Adult Treatment Panel III described in the 'Methods' section.

|| Three or more metabolic disturbances as listed above represent the MetS. Metabolic disturbances may range between 0 and 5.

60–1%. About 23% reported their health as being fair or poor. Socio-economic, lifestyle and health-related factors differed markedly by sex and by race, reflecting lower SES among African-Americans and women, and higher prevalence of risky healthy behaviours among men as well as among African-Americans. In terms of dietary intakes, overall, mean baseline dairy product servings/d was 1.02 (fluid milk (0.51), cheese (0.48) and yogurt (0.03)). Moreover, the three servings/d goal for dairy product consumption was reached by 6.6% of men and 3.8% of women ($P < 0.05$, χ^2 test), with lower proportions among African-Americans *v.* Whites, who consistently consumed less Ca, Mg, P and dairy product fat, as is the case for women *v.* men. With men having higher energetic intake than women, baseline intakes of orange vegetables, whole grains, nuts/seeds, soya and caffeine were lower among African-Americans, with a reverse trend observed for meat/poultry/fish and eggs.

Furthermore, hypertension was more prevalent among African-Americans *v.* Whites, whereas lipid profiles reflected poorer cardiometabolic health among Whites. Central obesity and the MetS were also more prevalent among Whites, although incidence proportions in metabolic outcomes did not differ by race.

Socio-demographic correlates of dairy product consumption and metabolic outcomes

Moreover, dairy product intake was higher among Whites and those with $>$ high school education, independently of age, sex and poverty status (Table 2). Nevertheless, above poverty status was directly linked to obesity and central obesity incidence, particularly among women. Both central obesity and MetS incidence rates increased with age, consistently among women, who simultaneously had lower incidence rates of both outcomes compared with men. Most notably, MetS incidence was lower among African-Americans *v.* Whites.

Dairy product consumption and incident metabolic outcomes

Furthermore, in the overall population, cheese and yogurt (both V1 and Δ) were directly related to central obesity incidence (Table 3), whereas Δdairy product fat was positively associated

with dyslipidaemia disturbances (TAG and HDL) and with MetS incidence. Moreover, higher milk consumption (both V1 and Δ) was inversely related to dyslipidaemia–TAG, whereas only its baseline value (i.e. All milk (V1)) was inversely related to the MetS, while being directly related to dyslipidaemia–HDL.

Sex-specific findings indicated some significant differentials in the relationship between dairy product intakes (including dairy-related nutrients) and MetD. Most notably, Δdairy product fat was inversely related with obesity among men while being positively related to dyslipidaemia–HDL among women ($P < 0.05$ for exposure \times sex interaction in a separate model with main effects).

Other relationships were race specific, including a 14% increased risk of central obesity with each 0.20 serving increase in baseline milk intake, observed in Whites only. Moreover, the positive association between Δdairy product fat and the MetS, as well as with dyslipidaemia–HDL, was restricted to Whites.

Discussion

Main findings

Our study uncovered some important findings regarding the relationship between dairy product consumption and various MetD, including the MetS. Specifically, in the overall urban adult population, both cheese and yogurt (V1 and Δ) were associated with an increased risk of central obesity. Baseline fluid milk intake (V1 in cup equivalents) was inversely related to the MetS (hazard ratio (HR) 0.86; 95% CI 0.78, 0.94), specifically to dyslipidaemia–TAG (HR 0.89; 95% CI 0.81, 0.99), although it was directly associated with dyslipidaemia–HDL-cholesterol (HR 1.10; 95% CI 1.01, 1.21). Furthermore, ΔCa and ΔP were inversely related to dyslipidaemia–HDL and MetS incidence, respectively, whereas Δdairy product fat was positively associated with incident TAG–dyslipidaemia and HDL-cholesterol–dyslipidaemia and the MetS. A few of those associations were sex and race specific.

Previous studies

Among recent cross-sectional studies, sixteen found an inverse relationship between dairy product consumption and adverse

Table 2. Associations of socio-demographic characteristics with baseline dairy product consumption, incident obesity, central obesity and the metabolic syndrome: Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS), 2004–2009 and 2009–2013* (Regression coefficients (β) with their standard errors; hazard ratios (HR) and 95% confidence intervals)

	Dairy product consumption (servings) (n 1371)			Obesity (n 859)			Central obesity (n 588)			Metabolic syndrome (n 1017)		
	β	SE	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
All subjects												
Men (v. women)	+0.28	0.22	0.22	0.75	0.52, 1.08	0.13	0.51	0.37, 0.70	<0.001	0.61	0.42, 0.89	0.011
Age (years)	-0.006	0.003	0.10	1.00	0.98, 1.02	0.78	1.02	1.00, 1.04	0.014	1.03	1.01, 1.05	0.018
African-American v. White	-0.54	0.06	<0.001	0.97	0.66, 1.45	0.90	1.10	0.78, 1.55	0.60	0.67	0.46, 0.98	0.038
Above v. below poverty	-0.05	0.10	0.61	2.02	1.34, 3.02	0.001	1.72	1.23, 2.43	0.002	1.26	0.85, 1.86	0.26
Education												
< High school	-			-			-			-		
High school	+0.14	0.10	0.22	1.01	0.44, 2.34	0.98	0.78	0.40, 1.53	0.47	0.79	0.40, 1.54	0.48
> High school	+0.35	0.11	0.001	0.89	0.37, 2.11	0.79	0.93	0.47, 1.84	0.83	0.84	0.42, 1.69	0.63
Men												
Age (years)	-0.008	0.010	0.41	1.02	0.99, 1.06	0.27	1.02	0.99, 1.05	0.21	1.04	1.00, 1.08	0.045
African-American v. White	-0.70	0.12	<0.001	0.66	0.35, 1.23	0.19	0.83	0.48, 1.43	0.50	0.64	0.33, 1.25	0.19
Above v. below poverty	+0.06	0.33	0.86	1.17	0.62, 2.20	0.62	1.56	0.93, 2.63	0.09	1.18	0.57, 2.46	0.65
Education												
< High school	-			-			-			-		
High school	+0.11	0.16	0.49	0.75	0.26, 2.20	0.60	0.60	0.25, 1.44	0.26	0.67	0.20, 2.27	0.52
> High school	+0.33	0.16	0.050	0.86	0.28, 2.63	0.78	0.79	0.32, 1.97	0.61	1.02	0.29, 3.56	0.98
Women												
Age (years)	+0.004	0.005	0.38	0.98	0.96, 1.10	0.22	1.03	1.00, 1.05	0.018	1.03	1.0, 1.05	0.021
African-American v. White	-0.53	0.07	<0.001	1.29	0.77, 2.16	0.34	1.24	0.77, 2.00	0.39	0.69	0.41, 1.09	0.11
Above v. below poverty	+0.22	0.15	0.15	2.93	1.71, 5.01	<0.001	2.03	1.27, 3.24	0.003	1.33	0.83, 2.12	0.24
Education												
< High school	-			-			-			-		
High school	+0.14	0.14	0.30	1.52	0.36, 6.39	0.57	0.99	0.33, 2.99	0.98	0.86	0.39, 1.92	0.72
> High school	+0.38	0.14	0.007	1.11	0.26, 4.76	0.89	1.00	0.36, 2.97	1.00	0.76	0.33, 1.76	0.52

* See Table 1 for definitions of obesity, central obesity and the metabolic syndrome. These were based on multivariate regression analyses. Linear regression was conducted for dairy product consumption, and Cox proportional hazards regression models was conducted for obesity, central obesity and the metabolic syndrome.

Table 3. 5-Year cases of incident metabolic disturbances by baseline and annual rates of change in dairy food and dairy-related nutrient intake among disturbance-free (at baseline) Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) participants: HANDLS 2004–2009 and 2009–2013* (Multivariable-adjusted hazard ratios (HR) and 95 % confidence intervals)

	Obesity		Central obesity		Hypertension		Hyperglycaemia		Dyslipidaemia–TAG		Dyslipidaemia–HDL		Metabolic syndrome†	
	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI
All subjects														
Model 1														
All milk (V1)	0.98	0.90, 1.06	1.00	0.75, 1.36	0.94	0.88, 1.00	0.93	0.83, 1.04	0.89‡	0.81, 0.99	1.10‡	1.01, 1.21	0.86‡	0.78, 0.94
Cheese (V1)	0.99	0.89, 1.10	1.13‡	1.05, 1.23	1.03	0.96, 1.11	0.99	0.88, 1.11	1.02	0.91, 1.14	1.01	0.90, 1.13	1.02	0.92, 1.13
Yogurt (V1)	0.97	0.87, 1.08	1.21‡	1.01, 1.44	1.01	0.93, 1.10	0.97	0.85, 1.12	1.05	0.95, 1.15	1.06	0.94, 1.20	0.94	0.85, 1.05
ΔAll milk	0.76	0.51, 1.15	1.01	0.75, 1.36	0.95	0.72, 1.27	0.93	0.60, 1.45	0.58‡	0.36, 0.93	1.32	0.94, 1.87	0.67	0.45, 1.02
ΔCheese	1.15	0.81, 1.64	1.90‡	1.47, 2.47	1.08	0.81, 1.45	0.78	0.51, 1.18	1.06	0.73, 1.53	0.95	0.63, 1.43	0.93	0.62, 1.41
ΔYogurt	0.87	0.63, 1.20	1.21‡	1.01, 1.44	0.99	0.79, 1.25	0.88	0.62, 1.25	1.17	0.93, 1.48	1.12	0.83, 1.51	1.04	0.81, 1.33
Model 2														
Ca (V1)	1.00	0.90, 1.08	1.02	0.95, 1.11	1.02	0.95, 1.11	1.01	0.91, 1.13	0.92	0.79, 1.07	0.98	0.89, 1.08	1.06	0.95, 1.18
P (V1)	0.98	0.82, 1.17	1.06	0.93, 1.21	1.04	0.92, 1.17	0.96	0.79, 1.15	0.98	0.78, 1.22	1.00	0.83, 1.21	0.82‡	0.68, 0.98
Mg (V1)	1.01	0.82, 1.17	0.96	0.91, 1.01	0.97	0.93, 1.02	0.95	0.88, 1.03	1.00	0.92, 1.09	1.00	0.93, 1.08	0.97	0.91, 1.04
Dairy product fat (V1)	0.98	0.88, 1.08	1.01	0.91, 1.11	0.97	0.89, 1.04	1.01	0.91, 1.13	1.14	0.99, 1.31	1.10	0.98, 1.24	1.05	0.95, 1.05
ΔCa	1.03	0.67, 1.58	1.14	0.79, 1.63	1.14	0.83, 1.56	0.93	0.62, 1.40	0.71	0.38, 1.32	0.71‡	0.51, 1.00	1.25	0.77, 2.03
ΔP	1.12	0.55, 2.25	1.14	0.64, 2.04	1.54	0.93, 2.53	1.31	0.65, 2.64	0.83	0.31, 2.18	1.43	0.71, 2.86	0.50	0.23, 1.10
ΔMg	0.88	0.68, 1.13	0.88	0.72, 1.08	0.86	0.73, 1.03	0.77	0.57, 1.04	0.92	0.65, 1.30	0.98	0.75, 1.29	0.86	0.65, 1.14
ΔDairy product fat	0.93	0.63, 1.36	1.31	0.93, 1.86	0.84	0.60, 1.17	1.00	0.65, 1.55	1.86‡	1.12, 3.08	1.87‡	1.28, 2.73	1.55‡	1.09, 2.21
Men														
Model 1														
All milk (V1)	0.94	0.81, 1.10	0.89‡	0.79, 0.99	0.92	0.84, 1.01	0.92	0.74, 1.14	0.73‡	0.58, 0.91	1.11	0.91, 1.35	0.76‡	0.63, 0.91
Cheese (V1)	1.17	0.68, 2.00	1.05	0.93, 1.18	1.00	0.90, 1.12	1.08	0.90, 1.29	1.14	0.97, 1.34	0.90	0.74, 1.10	1.0	0.86, 1.27
Yogurt (V1)	1.45§	0.97, 2.16	0.95	0.70, 1.29	0.98	0.83, 1.16	0.89	0.66, 1.20	1.41‡§	1.11, 1.80	1.16	0.95, 1.41	0.84	0.68, 1.04
ΔAll milk	0.61	0.31, 1.21	0.82	0.50, 1.32	0.90	0.61, 1.32	0.72	0.33, 1.56	0.22‡	0.08, 0.66	0.91§	0.44, 1.90	0.38‡	0.18, 0.77
ΔCheese	1.17	0.68, 2.00	1.84‡	1.27, 2.66	0.83	0.52, 1.31	1.16	0.62, 2.14	1.40	0.78, 2.51	0.94	0.46, 1.90	0.98	0.50, 1.91
ΔYogurt	1.45	0.97, 2.16	1.27	0.90, 1.79	0.66	0.37, 1.18	0.81	0.34, 1.92	1.51	0.92, 2.46	1.41	0.74, 2.68	1.07	0.55, 2.08
Model 2														
Ca (V1)	1.05§	0.81, 1.35	0.87	0.73, 1.04	0.95	0.82, 1.11	0.79	0.37, 1.67	0.61‡	0.44, 0.84	1.11	0.85, 1.44	0.94	0.71, 1.23
P (V1)	1.14§	0.79, 1.65	1.17	0.92, 1.11	1.12	0.90, 1.39	3.02	0.95, 9.60	1.30	0.85, 1.98	0.71	0.46, 1.10	1.08	0.71, 1.64
Mg (V1)	0.87§	0.75, 1.02	1.01	0.92, 1.11	0.91‡	0.83, 0.99	0.68	0.40, 1.16	1.05	0.90, 1.22	1.05	0.89, 1.23	0.92§	0.78, 1.09
Dairy product fat (V1)	0.75‡§	0.59, 0.96	0.98§	0.84, 1.15	0.97	0.84, 1.14	1.16	0.60, 2.26	1.48‡	1.14, 1.91	1.14	0.91, 1.43	0.94	0.76, 1.18
ΔCa	1.39	0.69, 2.80	0.94	0.53, 1.66	0.70	0.40, 1.21	0.79	0.37, 1.67	0.45	0.16, 1.24	1.29	0.53, 3.13	0.68	0.28, 1.66
ΔP	1.14	0.40, 3.29	1.48	0.62, 3.53	1.84	0.86, 3.94	3.02	0.95, 9.60	1.03	0.26, 4.00	0.31	0.07, 1.35	1.11§	0.24, 5.11
ΔMg	0.58‡	0.34, 0.98	1.05	0.75, 1.47	0.61‡	0.46, 0.82	0.68	0.40, 1.16	0.71	0.38, 1.32	1.32	0.78, 2.25	0.86§	0.49, 1.53
ΔDairy product fat	0.19‡§	0.08, 0.46	0.95	0.57, 1.59	0.76‡	0.46, 0.82	1.16	0.60, 2.26	3.66‡	1.45, 9.22	1.34§	0.60, 2.95	1.67	0.89, 3.14
Women														
Model 1														
All milk (V1)	1.05	0.91, 1.22	1.07	0.94, 1.21	0.90	0.81, 1.01	0.97	0.81, 1.15	0.87	0.73, 1.05	1.07	0.91, 1.27	0.80‡	0.71, 0.91
Cheese (V1)	0.97	0.82, 1.15	1.18‡	1.02, 1.37	1.04	0.92, 1.18	0.94	0.79, 1.13	0.90	0.70, 1.17	1.12	0.93, 1.36	1.00	0.86, 1.15
Yogurt (V1)	0.83‡	0.70, 0.99	0.96	0.86, 1.07	1.01	0.91, 1.13	1.07	0.91, 1.27	0.96	0.78, 1.17	1.06	0.85, 1.32	0.99	0.87, 1.12
ΔAll milk	1.00	0.53, 1.88	0.97	0.60, 1.57	0.88	0.53, 1.46	1.21	0.62, 2.38	0.50	0.21, 1.19	1.77	0.94, 3.34	0.62	0.34, 1.12
ΔCheese	1.42	0.82, 2.44	2.39‡	1.47, 3.99	1.29	0.82, 2.02	0.70	0.35, 1.38	0.47	0.19, 1.18	1.44	0.65, 3.20	0.87	0.49, 1.56
ΔYogurt	0.53	0.28, 1.01	1.36‡	1.03, 1.80	1.07	0.82, 1.39	1.04	0.67, 1.61	1.01	0.64, 1.60	1.22	0.82, 1.81	0.99	0.72, 1.37
Model 2														
Ca (V1)	0.99	0.86, 1.14	1.06	0.94, 1.20	1.13‡	1.01, 1.26	1.03	0.87, 1.22	1.19	0.96, 1.49	0.69‡	0.55, 0.86	1.19‡	1.01, 1.39
P (V1)	0.93	0.70, 1.23	1.00	0.80, 1.26	0.98	0.44, 2.19	0.80	0.59, 1.10	0.63‡	0.43, 0.93	1.90‡	1.30, 2.78	0.61‡	0.47, 0.80
Mg (V1)	1.02	0.93, 1.11	0.92	0.84, 1.00	1.01	0.79, 1.30	0.98	0.87, 1.11	0.99	0.87, 1.13	0.83‡	0.71, 0.96	0.98	0.91, 1.07
Dairy product fat (V1)	1.02	0.88, 1.18	1.00	0.86, 1.17	0.76	0.49, 1.18	1.06	0.89, 1.26	1.10	0.88, 1.36	1.08	0.88, 1.33	1.08	0.94, 1.25
ΔCa	0.86	0.43, 1.64	1.05	0.54, 2.05	1.88‡	1.15, 3.08	1.11	0.53, 2.32	1.90	0.65, 5.59	0.10‡	0.04, 0.24	1.82	0.90, 3.66
ΔP	2.09	0.61, 7.17	1.30	0.42, 3.99	0.98	0.44, 2.19	0.80	0.25, 2.57	0.12‡	0.02, 0.73	36.2‡	8.6, 151.8	0.24‡	0.08, 0.76
ΔMg	0.74	0.52, 1.05	0.69‡	0.49, 0.98	1.01	0.79, 1.30	0.83	0.51, 1.37	1.13	0.69, 1.87	0.45‡	0.25, 0.81	0.91	0.65, 1.27
ΔDairy product fat	1.55	0.94, 2.55	1.46	0.88, 2.43	0.76	0.49, 1.18	1.02	0.49, 2.12	1.51	0.67, 3.41	3.96	1.94, 8.04	1.59	0.94, 2.67



Table 3. Continued

	Obesity		Central obesity		Hypertension		Hyperglycaemia		Dyslipidaemia-TAG		Dyslipidaemia-HDL		Metabolic syndrome†	
	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI
Whites														
Model 1														
All milk (V1)	0.92	0.79, 1.06	1.14‡	1.00, 1.29	0.98	0.89, 1.18	0.80‡	0.65, 0.98	0.90	0.78, 1.03	1.07	0.91, 1.27	0.81‡	0.70, 0.92
Cheese (V1)	1.06	0.90, 1.24	1.15	0.99, 1.34	1.03	0.90, 1.18	0.79‡	0.63, 1.00	0.88	0.71, 1.07	1.12	0.93, 1.36	0.91	0.78, 1.06
Yogurt (V1)	0.90	0.77, 1.06	0.98	0.88, 1.09	1.01	0.89, 1.14	0.82	0.45, 1.47	1.03	0.91, 1.18	1.06	0.85, 1.32	0.94	0.79, 1.12
ΔAll milk	0.59	0.32, 1.08	1.10	0.69, 1.76	0.92	0.60, 1.43	0.61	0.29, 1.27	0.62	0.31, 1.22	1.77	0.94, 3.34	0.47‡	0.26, 0.85
ΔCheese	1.40	0.87, 2.27	2.11‡	1.33, 3.34	1.04	0.64, 1.70	0.40‡	0.17, 0.94	0.86	0.46, 1.64	1.44	0.65, 3.20	0.79	0.46, 1.38
ΔYogurt	0.85	0.57, 1.26	1.29	0.98, 1.70	0.97	0.71, 1.33	0.82	0.45, 1.47	1.27	0.90, 1.79	1.22	0.82, 1.81	0.83	0.59, 1.18
Model 2														
Ca (V1)	1.00	0.80, 1.26	1.10	0.94, 1.28	1.07	0.92, 1.24	0.88	0.60, 1.29	0.27‡	0.08, 0.94	0.87	0.57, 1.34	0.97	0.75, 1.27
P (V1)	1.09	0.77, 1.55	1.18	0.89, 1.56	1.02	0.79, 1.31	1.16	0.68, 1.96	0.78	0.17, 3.59	0.95	0.54, 1.68	0.80	0.55, 1.16
Mg (V1)	0.84‡	0.73, 0.96	0.87‡	0.79, 0.97	0.95	0.88, 1.03	0.81‡	0.69, 0.95	0.89	0.45, 1.75	0.99	0.85, 1.15	0.89	0.78, 1.01
Dairy product fat (V1)	0.98	0.82, 1.18	0.99	0.82, 1.19	0.91	0.88, 1.03	1.02	0.79, 1.31	1.24	0.58, 2.66	1.25	0.95, 1.64	1.10	0.92, 1.30
ΔCa	1.11	0.51, 2.41	1.64	0.76, 3.54	1.07	0.61, 1.89	0.56	0.19, 1.65	0.87	0.65, 1.16	0.28‡	0.09, 0.88	0.52	0.19, 1.46
ΔP	1.34	0.41, 4.36	0.92	0.28, 3.01	1.19	0.50, 2.80	1.49	0.38, 5.79	1.00	0.64, 1.54	1.50	0.29, 7.66	0.65	0.15, 2.82
ΔMg	0.41‡	0.24, 0.70	0.65‡	0.43, 0.98	0.96	0.73, 1.27	0.49‡	0.26, 0.94	0.92	0.78, 1.09	1.12	0.66, 1.90	0.68	0.39, 1.19
ΔDairy product fat	1.25	0.66, 2.36	1.64	0.81, 3.31	0.57	0.32, 1.03	1.90	0.74, 4.84	0.98	0.80, 1.20	4.10‡	2.07, 8.12	2.53‡	1.41, 4.57
AA														
Model 1														
All milk (V1)	1.14	0.98, 1.34	0.87	0.75, 1.00	0.87‡	0.79, 0.97	0.87	0.71, 1.06	0.69‡	0.51, 0.93	1.18	0.99, 1.40	0.87	0.72, 1.05
Cheese (V1)	0.99	0.54, 1.80	1.09	0.96, 1.25	0.99	0.88, 1.11	1.06	0.89, 1.25	1.15	0.89, 1.48	1.07	0.86, 1.34	1.04	0.86, 1.26
Yogurt (V1)	0.88	0.43, 1.78	0.99	0.77, 1.28	0.97	0.83, 1.12	1.09	0.93, 1.27	1.15	0.82, 1.60	0.98	0.77, 1.26	1.00	0.85, 1.16
ΔAll milk	1.24	0.64, 2.45	0.76	0.44, 1.34	0.78	0.49, 1.24	0.71	0.32, 1.58	0.15‡	0.04, 0.63	1.21	0.65, 2.26	0.73	0.35, 1.50
ΔCheese	0.99	0.54, 1.80	1.87‡	1.22, 2.88	1.24	0.81, 1.90	1.04	0.52, 2.06	1.19	0.53, 2.67	1.05	0.51, 2.19	0.71	0.35, 1.44
ΔYogurt	0.88	0.43, 1.78	1.28	0.84, 1.97	0.77	0.47, 1.25	1.05	0.61, 1.80	0.94	0.27, 3.28	1.63	0.90, 2.97	1.55	0.96, 2.49
Model 2														
Ca (V1)	0.99	0.83, 1.18	0.97	0.82, 1.14	1.04	0.93, 1.16	0.97	0.80, 1.17	0.80	0.57, 1.11	0.98	0.82, 1.18	1.52	0.79, 2.94
P (V1)	1.01	0.77, 1.32	1.10	0.88, 1.37	0.98	0.83, 1.15	1.05	0.94, 1.17	1.05	0.69, 1.61	1.21	0.90, 1.63	1.05	0.33, 3.35
Mg (V1)	1.13‡	1.02, 1.24	1.04	0.95, 1.13	0.95	0.89, 1.02	1.02	0.86, 1.21	1.07	0.92, 1.25	0.94	0.81, 1.08	0.85	0.58, 1.24
Dairy product fat (V1)	1.01	0.85, 1.18	1.02	0.88, 1.18	1.04	0.93, 1.15	1.05	1.01, 1.09	1.37‡	1.06, 1.77	1.09	0.91, 1.32	0.68	0.33, 1.42
ΔCa	0.92	0.46, 1.84	0.96	0.56, 1.65	1.31	0.86, 2.00	1.30	0.69, 2.46	0.49	0.16, 1.46	0.96	0.47, 1.95	1.06	0.88, 1.26
ΔP	1.45	0.53, 4.02	1.94	0.83, 4.57	1.38	0.72, 2.63	1.24	0.45, 3.41	1.66	0.31, 8.84	2.07	0.72, 5.91	0.92	0.68, 1.23
ΔMg	1.34	0.95, 1.91	1.02	0.76, 1.39	0.70‡	0.53, 0.93	1.03	0.69, 1.52	0.99	0.31, 1.66	0.72	0.43, 1.19	1.02	0.92, 1.14
ΔDairy product fat	0.94	0.51, 1.75	1.15	0.71, 1.87	1.20	0.79, 1.83	0.72	0.35, 1.48	2.38	0.95, 5.94	1.22	0.66, 2.27	0.95	0.79, 1.14

V1, baseline visit 1; AA, African-Americans; Δ, annual rate of change.

* See Table 1 for scaling of exposure variables in each model. Each model controls for age, sex, race, socio-economic status (education and poverty status), energy intake at baseline, current smoking, current drug use and self-rated health. Additional control was also made on the following major food group servings and nutrients (V1 and Δ): energy intake, total fruit, dark green vegetables, deep yellow vegetables, whole grains, non-whole grains, legumes, nuts/seeds, soya, total meat/poultry/fish, eggs, grams of discretionary solid fat, grams of discretionary oils, added sugars (teaspoons), alcoholic beverages (servings) and mg of caffeine.

† Based on National Cholesterol Education Program Adult Treatment Panel III criteria described in 'Methods' section.

‡ $P < 0.05$ for null hypothesis that $\log_e HR = 0$.

§ $P < 0.05$ for testing effect modification by sex, in separate models using interaction terms between exposure and each of the two effect modifiers.

|| $P < 0.05$ for testing effect modification by race, in separate models using interaction terms between exposure and each of the two effect modifiers.

metabolic outcomes (positive findings)^(34,47–62), whereas five had mixed findings^(71,74–78) and the remaining studies failed to detect an association in the expected direction^(79–81). Among positive findings, a study of 827 Iranian adults (18–74 years) concluded that the uppermost quartile of dairy product consumption (*v.* lowest) had reduced odds of central obesity, hypertension and the MetS, an association primarily mediated by Ca intake⁽³⁴⁾, as was replicated in a separate study⁽⁶⁰⁾. In a US study of adult women (*n* 10 006, ≥ 45 years), both Ca and dairy products' intakes were inversely related to the MetS, in multivariate-adjusted models⁽⁴⁷⁾. Similarly, a large Korean study (*n* 4862, ≥ 19 years) replicated those findings for milk and yogurt intake⁽⁵⁴⁾. Moreover, a large study of middle-aged adults (Brazilian Longitudinal Study of Adult Health, *n* 9835) concluded that a higher intake of total and full-fat dairy foods was inversely related to the MetS, and that dairy product SFA may be mediating this effect. Specifically, dairy product consumption was inversely related to blood pressure, glucose and TAG, and total dairy product consumption was positively associated with HDL-cholesterol among women⁽⁶²⁾. Mixed findings were echoed in a recent national study of US adults (the National Health and Nutrition Examination Surveys (NHANES 1999–2004)), whereby metabolic disorders were inversely related to whole milk, yogurt, Ca and Mg but positively associated with low-fat milk, cheese and P intakes⁽⁷¹⁾. Using NHANES 2001–2010, another study concluded that women meeting the RDA for Mg and Ca have lower odds of the MetS, unlike men who required above-RDA Ca intakes to be protected⁽⁷⁷⁾. The inverse relationship between full-fat dairy product consumption and insulin resistance was also observed in a study of 496 Japanese adults⁽⁵³⁾. Studies examining whole dietary patterns also suggested an inverse relationship of the dairy product-rich pattern with the MetS^(51,52,55,58,59).

Most selected cohort studies^(35,37–46,72,73) concluded that dairy product consumption, dairy-related nutrients or dietary patterns that include dairy product consumption are inversely related to the risk of the MetS and various MetD. For instance, after an average 3.2 years of follow-up, incident MetS among 1868 older adults was inversely related to low-fat dairy product intake and yogurt but positively related to cheese intake⁽³⁷⁾. Similarly, using data from the Framingham Offspring study (*n* 3440, baseline mean age: 54.5 years), Wang *et al.* found that total dairy product and yogurt intake were both related to over-time weight loss, as well as reduction in WC⁽³⁸⁾. In another follow-up study of Korean middle-aged adults (*n* 7240, average follow-up time: 45 months), higher baseline dairy product intake was associated with lower MetS risk and a reduction in WC over time⁽³⁹⁾. Regular fat dairy product intake was associated with lower MetS incidence, as was found in our secondary analysis, in another recent study of Australian middle-aged adults⁽⁴⁰⁾. In a large study combining data from the Atherosclerosis Risk in Communities study and the Multi-Ethnic Study of Atherosclerosis (*n* 13 444), incident hypertension was inversely related to P, particularly when derived from dairy products⁽⁴⁶⁾. Two selected cohort studies found little evidence of an association between dairy product consumption and MetD^(72,73).

Most relevant intervention trials^(63–68,82,83) detected a protective effect of dairy product consumption on metabolic end

points. In a 6- to 12-week follow-up study that randomised adults into three groups (*n* 25 (glucose control), *n* 20 (casein group), *n* 25 (whey group)), there were consistently faster reductions in TAG, insulin, insulin resistance and LDL-cholesterol over time in the whey group compared with controls⁽⁶⁶⁾. Those results were replicated in another smaller study (*n* 20 obese/overweight postmenopausal women) comparing whey and caseinate intervention *v.* glucose control on a wider array of metabolic outcomes. The protective effect of caseinate was found by a reduction in post-prandial TAG over time⁽⁶⁷⁾. Nevertheless, in a randomised cross-over study of thirty-five subjects (mean age 49.5 years), the milk/yogurt arm (*v.* fruit juice, fruit biscuit control) had limited effect on metabolic risk factors⁽⁸²⁾. This null finding was also replicated in an Australian randomised cross-over study (*n* 71, 18–75 years) of high dairy product intake *v.* low dairy product intake after 12 months of follow-up, measuring glucose, TAG and HDL-cholesterol among others⁽⁸³⁾.

Biological plausibility

Some of our key findings have plausible biological underlying mechanisms^(21,24,26–28). First, dairy products provides half of dietary Ca⁽²⁴⁾ and 1.1 $\mu\text{g}/100\text{ml}$ of vitamin D, which promotes Ca gut absorption and helps maintain adequate serum Ca and phosphate concentrations, thus enhancing bone mineralisation and preventing hypocalcaemia and secondary hyperparathyroidism⁽²⁴⁾. In fact, serum Ca is tightly regulated whereby minor decreases trigger normalisation by parathyroid hormone, which activates kidney 1α hydroxylase, thus converting 25-hydroxyvitamin D to its active form 1,25-dihydroxyvitamin D (1,25-OH₂-D)^(24,94). The latter induces rapid Ca ions (Ca²⁺) increase, inhibiting PPAR- γ expression, CCAAT/enhancer-binding protein α and steroid regulatory element-binding protein, which are strong inhibitory signals for adipogenesis and inflammation⁽⁹⁵⁾. A similar mechanism may also be responsible for the calciuretic effect of high-salt diets, which increase 1,25-OH₂-D and vascular smooth muscle intracellular Ca, thereby increasing peripheral vascular resistance and blood pressure⁽⁹⁶⁾. Second, dairy product are an important source of beneficial microbiota and two proteins, whey and casein, which along with branched-chain amino acids (e.g. leucine) improve complex indigestible polysaccharide utilisation and enhance the anti-obesity effects of Ca by suppressing plasma lipids, blood pressure, improving glucose homeostasis and ameliorating pro-inflammatory and oxidative stress^(37,97,98). Third, Ca from dairy products can also bind intestinal SCFA and bile acids causing up-regulation of the LDL receptor and thus reducing serum LDL-cholesterol concentration⁽²⁴⁾. The cholesterol-lowering effects of Ca accompanied by the effects of low-fat milk products enriched with plant stanol esters improve both total and LDL-cholesterol concentration in subjects with moderate hypercholesterolaemia^(24,99,100).

Moreover, Mg can modulate insulin action and secretion by preserving pancreatic β -cell function through their impact on Ca homeostasis and oxidative stress among others⁽¹⁰¹⁾. Mg can also raise serum HDL-cholesterol while reducing LDL-cholesterol and TAG, through increasing lipoprotein lipase



activity among others⁽¹⁰¹⁾. Mg's potential effect on weight maintenance was also reported, forming an un-absorbable soap with fatty acids and cholesterol, decreasing their absorption, and thus reducing energy intake from the diet⁽¹⁰¹⁾. Similarly, reduced serum phosphate level, partly ascribed to reduced P intake, is also a hallmark of the MetS, mostly the insulin resistance component as suggested elsewhere⁽¹⁰²⁾.

Strengths, limitations of the study and conclusions

Our study has several strengths, including its prospective design with long follow-up and repeated measures on exposures and outcomes. Further, we studied both major dairy foods and dairy-related nutrients, while distinguishing between low-fat and full milk in part of the analysis. Although fat content was available for all dairy products, we only considered varying fat contents of milk being the important contributor to total dairy product intake. Although small randomised trials have already been conducted, larger observational cohort studies remain clinically important to examine this research question over longer follow-up periods. Moreover, our study collected two 24-h dietary recalls/wave instead of one, reducing measurement error and enhancing the value of dietary variables in reflecting usual intake. Given the overall lower socio-economic status of our study sample, dairy product consumption was expected to be lower than the national average⁽⁷¹⁾. In fact, in both nationally representative data and this urban sample of US adults, educational attainment was an important factor determining dairy product intake, particularly among women. Our sample had almost half a serving lower mean intake of total dairy products compared with the national average, with <5% reaching the recommended three servings/d in total dairy product intake.

Despite its strengths, our study findings should be interpreted in light of some limitations. Some findings may be observed owing to selection bias, given that less than half of the original HANDLS sample was included in our present study. This was partly adjusted for using the two-stage Heckman selection model, as described in previous studies^(91–93). Moreover, measurement error in dietary exposures can still be sizeable, even though two 24-h recalls per wave are an improvement over many large cross-sectional studies. Those errors are probably random across MetD groups, leading to attenuation of true associations. Nevertheless, our findings regarding yogurt intake may not be as reliable as other dairy foods, given the low average consumption (<0.1 serving/d)⁽¹⁰³⁾. Additionally, data on supplemental intakes of Ca, Mg and P were not available for baseline data, which precluded the assessment to total intake of those nutrients. Our findings may be generalisable to urban adults in Baltimore city and other cities around the USA with similar racial composition. Finally, modest associations observed could be the result of residual confounding by unmeasured lifestyle or health-related factors, whereas other associations may have been left undetected owing to inadequate statistical power. In fact, dairy product intake may be a reflection of a healthy lifestyle measured by factors that were not accounted for in our analyses. It is worth noting that in addition to the commonly cited limitations of observational studies, many of the randomised trials to date have failed to use

an adequate comparison group that would reflect the dairy-related nutrients' potential effects on the MetS or its components, including Ca and Mg. It is therefore important to compare dairy product consumption with non-dairy products (e.g. soya products) and their potential effect on metabolic parameters over time. Instead, most randomised trials to date have compared individual constituents within dairy product (e.g. whey *v.* casein) or dairy product *v.* sugar-sweetened beverages. The latter cannot be considered a good comparison, as sugar-sweetened beverages are well-known to increase blood glucose, insulin and TAG over time⁽¹⁰⁴⁾. Although differential composition in Ca, Mg and P, as well as dairy product fat, may partially explain differences in the association between various dairy products and MetD, further studies are needed to uncover the key mediators.

In sum, various dairy product exposures had differential associations with MetD. Future intervention studies should uncover how changes in dairy product components over time may affect metabolic disorders, accounting for sex and race differences in those putative effects. Specifically, our study found that some dairy foods (yogurt and cheese) were directly associated, whereas milk was inversely related to the MetS and its components. Furthermore, minerals such as Ca and P are abundantly found in yogurt and cheese, as well as in milk. They are also found in other foods such as vegetables and whole grains. The latter food groups have been associated with lower incidence of major chronic diseases, and thus their consumption should be further encouraged. Replication of our findings by randomised controlled trials with similar exposures would strengthen the case for the public health implications of intakes of various dairy foods and related nutrients on populations and their potential impacts on metabolic disorders, including the MetS.

Acknowledgements

The authors thank Dr Ola S. Rostant and Nicolle Mode (NIA/NIH/IRP) for their internal review of the manuscript.

This work was fully supported by the Intramural Research Program of the NIH, National Institute on Aging.

M. A. B.: conceptualisation; literature search and review; data management; plan of analysis; statistical analysis; write-up of manuscript; and revision of the manuscript. M. T. F. K.: data acquisition; data management; plan of analysis; literature search and review; write-up of parts of manuscript; and revision of the manuscript. H. A. B., G. A. D. and J. A. C.: literature search and review; write-up of parts of the manuscript; and revision of the manuscript. M. K. E.: data acquisition and revision of the manuscript. A. B. Z.: data acquisition; plan of analysis; write-up of parts of the manuscript; and revision of the manuscript.

The authors declare that there are no conflicts of interest.

References

1. Grundy SM (1999) Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. *Am J Cardiol* **83**, 25F–29F.
2. Galassi A, Reynolds K & He J (2006) Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. *Am J Med* **119**, 812–819.

3. Alberti KG, Eckel RH, Grundy SM, *et al.* (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* **120**, 1640–1645.
4. Appels CW & Vandenbroucke JP (2006) Overweight, obesity, and mortality. *N Engl J Med* **355**, 2699; author reply 2700–2691.
5. Bender R, Zeeb H, Schwarz M, *et al.* (2006) Causes of death in obesity: relevant increase in cardiovascular but not in all-cancer mortality. *J Clin Epidemiol* **59**, 1064–1071.
6. Doig GS (2004) Obesity-related excess mortality: what should we do now? *Crit Care Med* **32**, 1084–1085.
7. Ferrucci L & Alley D (2007) Obesity, disability, and mortality: a puzzling link. *Arch Intern Med* **167**, 750–751.
8. Solomon CG & Manson JE (1997) Obesity and mortality: a review of the epidemiologic data. *Am J Clin Nutr* **66**, 1044S–1050S.
9. Stevens J (2000) Obesity and mortality in African-Americans. *Nutr Rev* **58**, 346–353.
10. Colditz GA (1999) Economic costs of obesity and inactivity. *Med Sci Sports Exerc* **31**, S663–S667.
11. Hill JO, Sallis JF & Peters JC (2004) Economic analysis of eating and physical activity: a next step for research and policy change. *Am J Prev Med* **27**, 111–116.
12. Wolf AM & Colditz GA (1998) Current estimates of the economic cost of obesity in the United States. *Obes Res* **6**, 97–106.
13. Crichton GE, Bryan J, Buckley J, *et al.* (2011) Dairy consumption and metabolic syndrome: a systematic review of findings and methodological issues. *Obes Rev* **12**, e190–e201.
14. Bray GA & Popkin BM (1998) Dietary fat intake does affect obesity! *Am J Clin Nutr* **68**, 1157–1173.
15. Heitmann BL, Lissner L, Sorensen TI, *et al.* (1995) Dietary fat intake and weight gain in women genetically predisposed for obesity. *Am J Clin Nutr* **61**, 1213–1217.
16. Kant AK, Graubard BI, Schatzkin A, *et al.* (1995) Proportion of energy intake from fat and subsequent weight change in the NHANES I Epidemiologic Follow-up Study. *Am J Clin Nutr* **61**, 11–17.
17. Maron DJ, Fair JM & Haskell WL (1991) Saturated fat intake and insulin resistance in men with coronary artery disease. The Stanford Coronary Risk Intervention Project Investigators and Staff. *Circulation* **84**, 2020–2027.
18. Miller WC, Lindeman AK, Wallace J, *et al.* (1990) Diet composition, energy intake, and exercise in relation to body fat in men and women. *Am J Clin Nutr* **52**, 426–430.
19. Pfeuffer M & Schrezenmeir J (2000) Bioactive substances in milk with properties decreasing risk of cardiovascular diseases. *Br J Nutr* **84**, Suppl. 1, S155–S159.
20. Aljefree N & Ahmed F (2015) Association between dietary pattern and risk of cardiovascular disease among adults in the Middle East and North Africa region: a systematic review. *Food Nutr Res* **59**, 27486.
21. Astrup A (2014) Yogurt and dairy product consumption to prevent cardiometabolic diseases: epidemiologic and experimental studies. *Am J Clin Nutr* **99**, 1235S–1242S.
22. Calton EK, James AP, Pannu PK, *et al.* (2014) Certain dietary patterns are beneficial for the metabolic syndrome: reviewing the evidence. *Nutr Res* **34**, 559–568.
23. Da Silva MS & Rudkowska I (2014) Dairy products on metabolic health: current research and clinical implications. *Maturitas* **77**, 221–228.
24. Dugan CE & Fernandez ML (2014) Effects of dairy on metabolic syndrome parameters: a review. *Yale J Biol Med* **87**, 135–147.
25. Kaleris M, Leung Yinko SS & Nedelcu R (2013) Dairy products and prevention of type 2 diabetes: implications for research and practice. *Front Endocrinol* **4**, 90.
26. Kratz M, Baars T & Guyenet S (2013) The relationship between high-fat dairy consumption and obesity, cardiovascular, and metabolic disease. *Eur J Nutr* **52**, 1–24.
27. Pal S & Radavelli-Bagatini S (2013) The effects of whey protein on cardiometabolic risk factors. *Obes Rev* **14**, 324–343.
28. Pfeuffer M & Schrezenmeir J (2007) Milk and the metabolic syndrome. *Obes Rev* **8**, 109–118.
29. Marques-Vidal P, Goncalves A & Dias CM (2006) Milk intake is inversely related to obesity in men and in young women: data from the Portuguese Health Interview Survey 1998–1999. *Int J Obes (Lond)* **30**, 88–93.
30. Rosell M, Johansson G, Berglund L, *et al.* (2004) Associations between the intake of dairy fat and calcium and abdominal obesity. *Int J Obes Relat Metab Disord* **28**, 1427–1434.
31. Elwood PC, Pickering JE & Fehily AM (2007) Milk and dairy consumption, diabetes and the metabolic syndrome: the Caerphilly prospective study. *J Epidemiol Community Health* **61**, 695–698.
32. Choi HK, Willett WC, Stampfer MJ, *et al.* (2005) Dairy consumption and risk of type 2 diabetes mellitus in men: a prospective study. *Arch Intern Med* **165**, 997–1003.
33. He K, Liu K, Daviglus ML, *et al.* (2006) Magnesium intake and incidence of metabolic syndrome among young adults. *Circulation* **113**, 1675–1682.
34. Azadbakht L, Mirmiran P, Esmailzadeh A, *et al.* (2005) Dairy consumption is inversely associated with the prevalence of the metabolic syndrome in Tehranian adults. *Am J Clin Nutr* **82**, 523–530.
35. Pereira MA, Jacobs DR Jr., Van Horn L, *et al.* (2002) Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. *JAMA* **287**, 2081–2089.
36. Ford ES, Mokdad AH & Liu S (2005) Healthy Eating Index and C-reactive protein concentration: findings from the National Health and Nutrition Examination Survey III, 1988–1994. *Eur J Clin Nutr* **59**, 278–283.
37. Babio N, Becerra-Tomas N, Martinez-Gonzalez MA, *et al.* (2015) Consumption of yogurt, low-fat milk, and other low-fat dairy products is associated with lower risk of metabolic syndrome incidence in an elderly Mediterranean population. *J Nutr* **145**, 2308–2316.
38. Wang H, Troy LM, Rogers GT, *et al.* (2014) Longitudinal association between dairy consumption and changes of body weight and waist circumference: the Framingham Heart Study. *Int J Obes* **38**, 299–305.
39. Shin H, Yoon YS, Lee Y, *et al.* (2013) Dairy product intake is inversely associated with metabolic syndrome in Korean adults: Anseong and Ansan cohort of the Korean Genome and Epidemiology Study. *J Korean Med Sci* **28**, 1482–1488.
40. Louie JC, Flood VM, Rangan AM, *et al.* (2013) Higher regular fat dairy consumption is associated with lower incidence of metabolic syndrome but not type 2 diabetes. *Nutr Metabol Cardiovasc Dis* **23**, 816–821.
41. Hsiao PY, Mitchell DC, Coffman DL, *et al.* (2013) Dietary patterns and relationship to obesity-related health outcomes and mortality in adults 75 years of age or greater. *J Nutr Health Aging* **17**, 566–572.
42. Holmberg S & Thelin A (2013) High dairy fat intake related to less central obesity: a male cohort study with 12 years' follow-up. *Scand J Prim Health Care* **31**, 89–94.

43. Baik I, Lee M, Jun NR, *et al.* (2013) A healthy dietary pattern consisting of a variety of food choices is inversely associated with the development of metabolic syndrome. *Nutr Res Pract* **7**, 233–241.
44. Sherafat-Kazemzadeh R, Egtesadi S, Mirmiran P, *et al.* (2010) Dietary patterns by reduced rank regression predicting changes in obesity indices in a cohort study: Tehran Lipid and Glucose Study. *Asia Pac J Clin Nutr* **19**, 22–32.
45. Mozaffarian D, Cao H, King IB, *et al.* (2010) Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. *Ann Intern Med* **153**, 790–799.
46. Alonso A, Nettleton JA, Ix JH, *et al.* (2010) Dietary phosphorus, blood pressure, and incidence of hypertension in the atherosclerosis risk in communities study and the multi-ethnic study of atherosclerosis. *Hypertension* **55**, 776–784.
47. Liu S, Song Y, Ford ES, *et al.* (2005) Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. *Diabetes Care* **28**, 2926–2932.
48. Beydoun MA, Boueiz A, Shroff MR, *et al.* (2010) Associations among 25-hydroxyvitamin D, diet quality, and metabolic disturbance differ by adiposity in adults in the United States. *J Clin Endocrinol Metab* **95**, 3814–3827.
49. Kwon HT, Lee CM, Park JH, *et al.* (2010) Milk intake and its association with metabolic syndrome in Korean: analysis of the third Korea National Health and Nutrition Examination Survey (KNHANES III). *J Korean Med Sci* **25**, 1473–1479.
50. Tidwell DK & Valliant MW (2011) Higher amounts of body fat are associated with inadequate intakes of calcium and vitamin D in African American women. *Nutr Res* **31**, 527–536.
51. Hong S, Song Y, Lee KH, *et al.* (2012) A fruit and dairy dietary pattern is associated with a reduced risk of metabolic syndrome. *Metabol Clin Exp* **61**, 883–890.
52. Setayeshgar S, Whiting SJ & Vatanparast H (2012) Metabolic syndrome in Canadian adults and adolescents: prevalence and associated dietary intake. *ISRN Obes* **2012**, 816846.
53. Akter S, Kurotani K, Nanri A, *et al.* (2013) Dairy consumption is associated with decreased insulin resistance among the Japanese. *Nutr Res* **33**, 286–292.
54. Kim J (2013) Dairy food consumption is inversely associated with the risk of the metabolic syndrome in Korean adults. *J Human Nutr Diet* **26**, Suppl. 1, 171–179.
55. Arisawa K, Uemura H, Yamaguchi M, *et al.* (2014) Associations of dietary patterns with metabolic syndrome and insulin resistance: a cross-sectional study in a Japanese population. *J Med Invest* **61**, 333–344.
56. Crichton GE & Alkerwi A (2014) Whole-fat dairy food intake is inversely associated with obesity prevalence: findings from the Observation of Cardiovascular Risk Factors in Luxembourg study. *Nutr Res* **34**, 936–943.
57. Crichton GE & Alkerwi A (2014) Dairy food intake is positively associated with cardiovascular health: findings from Observation of Cardiovascular Risk Factors in Luxembourg study. *Nutr Res* **34**, 1036–1044.
58. Choi JH, Woo HD, Lee JH, *et al.* (2015) Dietary patterns and risk for metabolic syndrome in Korean women: a cross-sectional study. *Medicine* **94**, e1424.
59. Grosso G, Stepaniak U, Micek A, *et al.* (2015) A Mediterranean-type diet is associated with better metabolic profile in urban Polish adults: results from the HAPIEE study. *Metabol Clin Exp* **64**, 738–746.
60. Martins ML, Kac G, Silva RA, *et al.* (2015) Dairy consumption is associated with a lower prevalence of metabolic syndrome among young adults from Ribeirao Preto, Brazil. *Nutrition* **31**, 716–721.
61. Song S, Kim EK, Hong S, *et al.* (2015) Low consumption of fruits and dairy foods is associated with metabolic syndrome in Korean adults from outpatient clinics in and near Seoul. *Nutr Res Pract* **9**, 554–562.
62. Drehmer M, Pereira MA, Schmidt MI, *et al.* (2016) Total and full-fat, but not low-fat, dairy product intakes are inversely associated with metabolic syndrome in adults. *J Nutr* **146**, 81–89.
63. Drouin-Chartier JP, Gagnon J, Labonte ME, *et al.* (2015) Impact of milk consumption on cardiometabolic risk in postmenopausal women with abdominal obesity. *Nutr J* **14**, 12.
64. Jones KW, Eller LK, Pamell JA, *et al.* (2013) Effect of a dairy- and calcium-rich diet on weight loss and appetite during energy restriction in overweight and obese adults: a randomized trial. *Eur J Clin Nutr* **67**, 371–376.
65. Lee YJ, Seo JA, Yoon T, *et al.* (2016) Effects of low-fat milk consumption on metabolic and atherogenic biomarkers in Korean adults with the metabolic syndrome: a randomised controlled trial. *J Human Nutr Diet* **29**, 477–486.
66. Pal S, Ellis V & Dhaliwal S (2010) Effects of whey protein isolate on body composition, lipids, insulin and glucose in overweight and obese individuals. *Br J Nutr* **104**, 716–723.
67. Pal S, Ellis V & Ho S (2010) Acute effects of whey protein isolate on cardiovascular risk factors in overweight, postmenopausal women. *Atherosclerosis* **212**, 339–344.
68. van Meijl LE & Mensink RP (2011) Low-fat dairy consumption reduces systolic blood pressure, but does not improve other metabolic risk parameters in overweight and obese subjects. *Nutr Metabol Cardiovasc Dis* **21**, 355–361.
69. Steffen LM, Kroenke CH, Yu X, *et al.* (2005) Associations of plant food, dairy product, and meat intakes with 15-y incidence of elevated blood pressure in young black and white adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. *Am J Clin Nutr* **82**, 1169–1177; quiz 1363–1364.
70. Rajpathak SN, Rimm EB, Rosner B, *et al.* (2006) Calcium and dairy intakes in relation to long-term weight gain in US men. *Am J Clin Nutr* **83**, 559–566.
71. Beydoun MA, Gary TL, Caballero BH, *et al.* (2008) Ethnic differences in dairy and related nutrient consumption among US adults and their association with obesity, central obesity, and the metabolic syndrome. *Am J Clin Nutr* **87**, 1914–1925.
72. Sayon-Orea C, Bes-Rastrollo M, Marti A, *et al.* (2015) Association between yogurt consumption and the risk of metabolic syndrome over 6 years in the SUN study. *BMC Public Health* **15**, 170.
73. Snijder MB, van Dam RM, Stehouwer CD, *et al.* (2008) A prospective study of dairy consumption in relation to changes in metabolic risk factors: the Hoorn Study. *Obesity* **16**, 706–709.
74. Snijder MB, van der Heijden AA, van Dam RM, *et al.* (2007) Is higher dairy consumption associated with lower body weight and fewer metabolic disturbances? The Hoorn Study. *Am J Clin Nutr* **85**, 989–995.
75. Abreu S, Moreira P, Moreira C, *et al.* (2014) Intake of milk, but not total dairy, yogurt, or cheese, is negatively associated with the clustering of cardiometabolic risk factors in adolescents. *Nutr Res* **34**, 48–57.
76. Alegria-Lertxundi I, Rocandio Pablo A & Arroyo-Izaga M (2014) Cheese consumption and prevalence of overweight and obesity in a Basque adult population: a cross-sectional study. *Int J Food Sci Nutr* **65**, 21–27.
77. Moore-Schiltz L, Albert JM, Singer ME, *et al.* (2015) Dietary intake of calcium and magnesium and the metabolic syndrome in the National Health and Nutrition Examination (NHANES) 2001–2010 data. *Br J Nutr* **114**, 924–935.

78. Shin BR, Choi YK, Kim HN, *et al.* (2016) High dietary calcium intake and a lack of dairy consumption are associated with metabolic syndrome in obese males: the Korean National Health and Nutrition Examination Survey 2010 to 2012. *Nutr Res* **36**, 518–525.
79. Sun J, Buys N & Shen S (2013) Dietary patterns and cardiovascular disease-related risks in Chinese older adults. *Front Public Health* **1**, 48.
80. Kimokoti RW, Judd SE, Shikany JM, *et al.* (2014) Food intake does not differ between obese women who are metabolically healthy or abnormal. *J Nutr* **144**, 2018–2026.
81. Ghotboddin Mohammadi S, Mirmiran P, Bahadoran Z, *et al.* (2015) The association of dairy intake with metabolic syndrome and its components in adolescents: Tehran Lipid and Glucose Study. *Int J Endocrinol Metabol* **13**, e25201.
82. van Meijl LE & Mensink RP (2010) Effects of low-fat dairy consumption on markers of low-grade systemic inflammation and endothelial function in overweight and obese subjects: an intervention study. *Br J Nutr* **104**, 1523–1527.
83. Crichton GE, Howe PR, Buckley JD, *et al.* (2012) Dairy consumption and cardiometabolic health: outcomes of a 12-month crossover trial. *Nutr Metabol* **9**, 19.
84. Evans MK, Lepkowski JM, Powe NR, *et al.* (2010) Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS): overcoming barriers to implementing a longitudinal, epidemiologic, urban study of health, race, and socioeconomic status. *Ethn Dis* **20**, 267–275.
85. Moshfegh AJ, Rhodes DG, Baer DJ, *et al.* (2008) The US Department of Agriculture Automated Multiple-Pass Method reduces bias in the collection of energy intakes. *Am J Clin Nutr* **88**, 324–332.
86. US Department of Agriculture ARS (2016) Food Surveys Research Group, USDA. Food and nutrient database for dietary studies, 3.0. <http://www.ars.usda.gov/Services/docs.htm?docid=12089> (accessed January 2017).
87. Wang Y & Beydoun MA (2007) The obesity epidemic in the United States – gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. *Epidemiol Rev* **29**, 6–28.
88. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* **285**, 2486–2497.
89. Stata (2015) *Statistics/Data Analysis: Release 14.0*. College Station, TX: Stata Corporation.
90. Heckman JJ (1979) Sample selection bias as a specification error. *Econometrica* **47**, 153–161.
91. Beydoun MA, Canas JA, Dore GA, *et al.* (2016) Serum uric acid and its association with longitudinal cognitive change among urban adults. *J Alzheimers Dis* **52**, 1415–1430.
92. Beydoun MA, Fanelli Kuczmarski MT, Beydoun HA, *et al.* (2015) Associations of the ratios of *n*-3 to *n*-6 dietary fatty acids with longitudinal changes in depressive symptoms among US women. *Am J Epidemiol* **181**, 691–705.
93. Beydoun MA, Beydoun HA, Rostant OS, *et al.* (2015) Thyroid hormones are associated with longitudinal cognitive change in an urban adult population. *Neurobiol Aging* **36**, 3056–3066.
94. Zemel MB (2003) Mechanisms of dairy modulation of adiposity. *J Nutr* **133**, 252S–256S.
95. Jensen B, Farach-Carson MC, Kenaley E, *et al.* (2004) High extracellular calcium attenuates adipogenesis in 3T3-L1 preadipocytes. *Exp Cell Res* **301**, 280–292.
96. Zemel MB (2001) Calcium modulation of hypertension and obesity: mechanisms and implications. *J Am Coll Nutr* **20**, 428S–435S discussion 440S–442S.
97. Yoda K, Sun X, Kawase M, *et al.* (2015) A combination of probiotics and whey proteins enhances anti-obesity effects of calcium and dairy products during nutritional energy restriction in aP2-agouti transgenic mice. *Br J Nutr* **113**, 1689–1696.
98. Zemel MB, Richards J, Mathis S, *et al.* (2005) Dairy augmentation of total and central fat loss in obese subjects. *Int J Obes (Lond)* **29**, 391–397.
99. Hunter JE, Zhang J & Kris-Etherton PM (2010) Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review. *Am J Clin Nutr* **91**, 46–63.
100. Seppo L, Jauhiainen T, Nevala R, *et al.* (2007) Plant stanol esters in low-fat milk products lower serum total and LDL cholesterol. *Eur J Nutr* **46**, 111–117.
101. Sarrafzadegan N, Khosravi-Boroujeni H, Lotfizadeh M, *et al.* (2016) Magnesium status and the metabolic syndrome: a systematic review and meta-analysis. *Nutrition* **32**, 409–417.
102. Kalaitzidis R, Tsimihodimos V, Bairaktari E, *et al.* (2005) Disturbances of phosphate metabolism: another feature of metabolic syndrome. *Am J Kidney Dis* **45**, 851–858.
103. Thiebaut AC, Kipnis V, Schatzkin A, *et al.* (2008) The role of dietary measurement error in investigating the hypothesized link between dietary fat intake and breast cancer – a story with twists and turns. *Cancer Invest* **26**, 68–73.
104. Narain A, Kwok CS & Mamas MA (2017) Soft drink intake and the risk of metabolic syndrome: a systematic review and meta-analysis. *Int J Clin Pract* **71**, e12927.

